Alain C Borczuk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/864889/publications.pdf

Version: 2024-02-01

194 papers	16,212 citations	22099 59 h-index	18606 119 g-index
202 all docs	202 docs citations	202 times ranked	25064 citing authors

#	Article	IF	Citations
1	Elastin in pulmonary pathology: relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint. Histopathology, 2022, 80, 457-467.	1.6	15
2	Updates in grading and invasion assessment in lung adenocarcinoma. Modern Pathology, 2022, 35, 28-35.	2.9	14
3	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology, 2022, 17, 362-387.	0.5	429
4	Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination. Cancer Research, 2022, 82, 1365-1379.	0.4	11
5	System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell Reports Medicine, 2022, 3, 100522.	3.3	24
6	Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers, 2022, 14, 708.	1.7	8
7	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in nonâ€“small cell lung cancer. Science Translational Medicine, 2022, 14, eabe8195.	5.8	16
8	Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. EBioMedicine, 2022, 77, 103894.	2.7	12
9	Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. Nature Communications, 2022, 13, 1592.	5.8	16
10	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	0.5	6
11	Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma. Cell Reports, 2022, 39, 110639.	2.9	15
12	Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. American Journal of Pathology, 2022, 192, 1001-1015.	1.9	19
13	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Science Translational Medicine, 2022, 14, .	5.8	129
14	Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1336-1352.	2.5	28
15	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
16	Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature, 2021, 589, 270-275.	13.7	389
17	Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology, 2021, 88, 56-68.	1.9	111
18	Therapeutic Interception of Early Lung Adenocarcinoma Progression: Not Just How, but When?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 8-9.	2.5	1

#	Article	IF	Citations
19	Frozen Section in Lung and Pleural Pathology. , 2021, , 225-245.		0
20	Pulmonary pathology of COVID-19: a review of autopsy studies. Current Opinion in Pulmonary Medicine, 2021, 27, 184-192.	1.2	47
21	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature Communications, 2021, 12, 1660.	5.8	132
22	The spatial landscape of lung pathology during COVID-19 progression. Nature, 2021, 593, 564-569.	13.7	249
23	MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opinion on Therapeutic Targets, 2021, 25, 249-268.	1.5	22
24	A molecular single-cell lung atlas of lethal COVID-19. Nature, 2021, 595, 114-119.	13.7	411
25	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	0.5	13
26	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. Circulation Research, 2021, 129, 33-46.	2.0	40
27	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncology, The, 2021, 22, 824-835.	5.1	191
28	Cytokine signatures of end organ injury in COVID-19. Scientific Reports, 2021, 11, 12606.	1.6	24
29	Tissue factor upregulation is associated with SARSâ€CoVâ€2 in the lungs of COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 2268-2274.	1.9	32
30	L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. JCI Insight, 2021, 6, .	2.3	31
31	SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metabolism, 2021, 33, 1577-1591.e7.	7.2	123
32	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secretingÂCCL2. Stem Cell Reports, 2021, 16, 2274-2288.	2.3	37
33	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. Journal of Leukocyte Biology, 2021, 110, 21-26.	1.5	82
34	Alain C. Borczuk, MD, Assumes Editorship of Archives. Archives of Pathology and Laboratory Medicine, 2021, 145, 10-10.	1.2	1
35	Chondroid lipoma: multimodality imaging in a 9-year-old female. Skeletal Radiology, 2020, 49, 161-169.	1.2	1
36	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203

#	Article	IF	Citations
37	The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2020, 9, 55-61.	0.2	1
38	Pulmonary Neuroendocrine Tumors. Surgical Pathology Clinics, 2020, 13, 35-55.	0.7	14
39	Genomic Underpinnings of Tumor Behavior in In Situ and Early Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 697-706.	2.5	32
40	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. Journal of Experimental Medicine, 2020, 217, .	4.2	1,193
41	COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern Pathology, 2020, 33, 2156-2168.	2.9	380
42	A case series on inflammatory cardiomyopathy and suspected cardiac sarcoidosis: role of cardiac PET in management. European Heart Journal - Case Reports, 2020, 4, 1-9.	0.3	2
43	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 2020, 182, 429-446.e14.	13.5	1,257
44	Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma. Journal of the American Society of Cytopathology, 2020, 9, 146-151.	0.2	13
45	Clinical significance of blueâ€green neutrophil and monocyte cytoplasmic inclusions in SARSâ€CoVâ€2 positive critically ill patients. British Journal of Haematology, 2020, 190, e89-e92.	1.2	24
46	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
47	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell, 2020, 27, 125-136.e7.	5.2	543
48	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. Archives of Pathology and Laboratory Medicine, 2020, 144, 1392-1396.	1.2	31
49	Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 2020, 136, 1169-1179.	0.6	1,071
50	Nextâ€generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study. Cancer Cytopathology, 2020, 128, 840-851.	1.4	6
51	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
52	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. Archives of Pathology and Laboratory Medicine, 2020, 144, 1477-1489.	1.2	14
53	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. Annals of the American Thoracic Society, 2020, 17, 550-554.	1.5	17
54	Higher Tissue Factor (TF) Expression in the Lungs of COVID-19 Pneumonia Patients Than Patients with Acute Respiratory Distress Syndrome: Association with Thrombi Formation. Blood, 2020, 136, 4-4.	0.6	3

#	Article	IF	Citations
55	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. Archives of Pathology and Laboratory Medicine, 2020, 144, 1535-1546.	1.2	10
56	Insulinoma-associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2019, 8, 299-308.	0.2	25
57	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	1.4	78
58	Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists. Annals of Diagnostic Pathology, 2019, 41, 43-50.	0.6	8
59	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212
60	A Man in His 20s With Cough, Unilateral Pleural Effusion, and Nodular Pleural Thickening. Chest, 2019, 156, e121-e126.	0.4	0
61	Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2019, 8, 39-46.	0.2	13
62	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1â€“Negative Human Lung Cancers. Clinical Cancer Research, 2018, 24, 1954-1964.	3.2	64
63	Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. Journal of Clinical Pathology, 2018, 71, 626-630.	1.0	26
64	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	0.5	33
65	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	1.2	70
66	Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. Archives of Pathology and Laboratory Medicine, 2018, 142, 236-242.	1.2	61
67	Keeping Up With Testing Guidelines in Lung Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 783-784.	1.2	1
68	Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 914-921.	1.2	24
69	Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function. American Journal of Human Genetics, 2018, 103, 100-114.	2.6	34
70	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	0.5	589
71	Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nature Medicine, 2018, 24, 770-781.	15.2	121
72	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	0.8	24

#	Article	IF	Citations
73	Precursor and Preinvasive Lesions. Molecular Pathology Library, 2018, , 213-231.	0.1	0
74	Molecular Pathology of Uncommon Carcinomas. Molecular Pathology Library, 2018, , 183-197.	0.1	0
75	Sarcomatous Diffuse Malignant Mesothelioma, Pleural. Encyclopedia of Pathology, 2018, , 367-374.	0.0	0
76	Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, 628-635.	1.5	28
77	Challenges of Frozen Section in Thoracic Pathology: Lepidic Lesions, Limited Resections, and Margins. Archives of Pathology and Laboratory Medicine, 2017, 141, 932-939.	1.2	10
78	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	0.5	113
79	METâ€“GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 7084-7096.	3.2	12
80	Reproducibility for histologic parameters in peritoneal mesothelioma. Human Pathology, 2017, 67, 54-59.	1.1	10
81	Focusing on Preinvasive Neoplasia: A Molecular Frontier at the Pathologist's Fingertips. Archives of Pathology and Laboratory Medicine, 2017, 141, 1604-1605.	1.2	1
82	Use of Oncogenic Driver Mutations in Staging ofÂMultiple Primary Lung Carcinomas: A Single-Center Experience. Journal of Thoracic Oncology, 2017, 12, 1524-1535.	0.5	39
83	Genome-wide association study of subclinical interstitial lung disease in MESA. Respiratory Research, 2017, 18, 97.	1.4	31
84	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. Clinical Cancer Research, 2017, 23, 825-832.	3.2	78
85	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal of Clinical Investigation, 2017, 127, 2081-2090.	3.9	155
86	Abstract 1217: Blockade of Aurora kinase A synergizes with platinum and radiation in non-small cell lung cancer cells. , 2017, , .		0
87	Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology, 2016, 68, 729-737.	1.6	26
88	Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Archives of Pathology and Laboratory Medicine, 2016, 140, 1104-1110.	1.2	24
89	Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. European Respiratory Review, 2016, 25, 364-371.	3.0	39
90	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	1.2	95

#	Article	IF	Citations
91	Cryobiopsy in the Diagnosis of Interstitial Lung Disease. A Step Forward or Back?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 707-709.	2.5	25
92	Programmed Death Ligand-1 Immunohistochemistryâ€" A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	1.2	107
93	Pulmonary Kirsten Rat Sarcoma Virus Mutation Positive Mucinous Adenocarcinoma Arising in aÂCongenital Pulmonary AirwayÂMalformation, Mixed Type 1 and 2. Annals of Thoracic Surgery, 2016, 102, e335-e337.	0.7	13
94	Over- and Underdiagnosis in Lung Cancer: Searching for a â€œSolidâ€•Diagnosis. Radiology, 2016, 280, 655-658.	3.6	1
95	An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 2016, 5, 2641-2648.	1.3	25
96	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1281-1284.	1.2	26
97	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPÎ± expression. Science Translational Medicine, 2016, 8, 350ra104.	5.8	45
98	Routine molecular testing of resected early-stage lung adenocarcinoma with targeted next-generation sequencing demonstrates a high rate of actionable mutations. Journal of Thoracic Oncology, 2016, 11, S44-S45.	0.5	1
99	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. Archives of Pathology and Laboratory Medicine, 2016, 140, 351-354.	1.2	12
100	Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology and Therapy, 2016, 17, 328-335.	1.5	47
101	Recent advances in the management of pulmonary sarcomatoid carcinoma. Expert Review of Respiratory Medicine, 2016, 10, 407-416.	1.0	23
102	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. Journal of Clinical Oncology, 2016, 34, 794-802.	0.8	287
103	Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget, 2016, 7, 28976-28988.	0.8	74
104	Has MET met its match?. Annals of Translational Medicine, 2016, 4, 97-97.	0.7	4
105	Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer. , 2016, , .		0
106	Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition.. Journal of Clinical Oncology, 2015, 33, 8020-8020.	0.8	3
107	Long-term outcomes of cytoreduction and HIPEC for malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2015, 33, 4111-4111.	0.8	0
108	Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer. , 2015, , .		0

#	Article	IF	Citations
109	Abstract 696: Comprehensive genomic analysis identifies frequent MET juxtamembrane domain deletions as an actionable genomic alteration in pulmonary sacromatoid carcinoma. , 2015, , .		0
110	Genomic Alterations in Pulmonary Adenocarcinoma In Situ in an Adolescent Patient. Archives of Pathology and Laboratory Medicine, 2014, 138, 559-563.	1.2	1
111	Well-differentiated Papillary Mesothelioma With Invasive Foci. American Journal of Surgical Pathology, 2014, 38, 990-998.	2.1	72
112	Thoracoscopic lobectomy for type I pleuropulmonary blastoma in an infant. Pediatric Surgery International, 2014, 30, 239-242.	0.6	8
113	Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation, 2014, 94, 129-137.	1.7	188
114	EIF2AK4 Mutations in Pulmonary Capillary Hemangiomatosis. Chest, 2014, 145, 231-236.	0.4	176
115	Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive genomic profiling.. Journal of Clinical Oncology, 2014, 32, 8073-8073.	0.8	0
116	A two-stage, open-label, phase II study of bortezomib plus oxaliplatin in previously treated patients with malignant pleural or peritoneal mesothelioma.. Journal of Clinical Oncology, 2014, 32, e22191-e22191.	0.8	0
117	Abstract 3526: The mTORC2 component RICTOR plays a key role in lung cancer cell growth. , 2014, , .		0
118	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	13.9	412
119	PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis, 2013, 34, 739-749.	1.3	81
120	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Nonâ€“Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Archives of Pathology and Laboratory Medicine, 2013, 137, 32-40.	1.2	54
121	Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Modern Pathology, 2013, 26, 239-246.	2.9	18
122	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	32
123	Comparative Anatomy of Chromosomal Domains with Imprinted and Non-Imprinted Allele-Specific DNA Methylation. PLoS Genetics, 2013, 9, e1003622.	1.5	47
124	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2013, 137, 647-667.	1.2	422
125	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	20
126	Abstract LB-46: C/EBPÎ± acts as tumor suppressor in lung cancer by inhibiting the proto-oncogene Bmi-1.. , 2013, , .		0

#	Article	IF	Citations
127	Neoplastic and Nonneoplastic Benign Mass Lesions of the Lung. Archives of Pathology and Laboratory Medicine, 2012, 136, 1227-1233.	1.2	9
128	Diagnostic Patient Care, Not Just Diagnosis. Archives of Pathology and Laboratory Medicine, 2012, 136, 711-712.	1.2	0
129	Utility of Glucose Transporter 1 in the Distinction of Benign and Malignant Thoracic and Abdominal Mesothelial Lesions. Archives of Pathology and Laboratory Medicine, 2012, 136, 804-809.	1.2	30
130	Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension. Circulation: Cardiovascular Genetics, 2012, 5, 336-343.	5.1	333
131	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology, 2012, 25, 1574-1583.	2.9	206
132	Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Modern Pathology, 2012, 25, S1-S10.	2.9	40
133	Cytokine-Like Factor 1 Gene Expression Is Enriched in Idiopathic Pulmonary Fibrosis and Drives the Accumulation of CD4+ T Cells in Murine Lungs. American Journal of Pathology, 2012, 180, 1963-1978.	1.9	42
134	Molecular Basis for the Current Lung Cancer Classification. Molecular Pathology Library, 2012, , 75-85.	0.1	0
135	Abstract 4690: PARP inhibition increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancers. , 2012, , .		1
136	Molecular Pathology of Large Cell Carcinoma. Molecular Pathology Library, 2012, , 169-183.	0.1	0
137	In situ distribution of metallic platinum in tumor tissues after intraperitoneal platinum chemotherapy assessed by digital synchrotron-abetted x-ray fluorescence microscopy.. Journal of Clinical Oncology, 2012, 30, e13067-e13067.	0.8	0
138	Do all lung adenocarcinomas follow a stepwise progression?. Lung Cancer, 2011, 74, 7-11.	0.9	110
139	Loss Of The Transforming Growth Factor-Beta (TGF-) Receptor In The Mutated K-RAS Orthotopic Model Of Murine Lung Cancer Parallels The Progression Of Human Bronchioloalveolar Cell Carcinoma To Invasive Adenocarcinoma. , 2011, , .		0
140	Cpap In The Management Of A 5-Month-Old With Late Clinical Presentation Of Primary Pulmonary Lymphangiectasia. , 2011, , .		0
141	Cytokine-Like Factor I (CLF1) Expression Is Increased In Idiopathic Pulmonary Fibrosis (IPF) And Promotes Inflammation But Decreases Fibrosis In Bleomycin Injury. , 2011, , .		0
142	Lung Pathologic Findings in a Local Residential and Working Community Exposed to World Trade Center Dust, Gas, and Fumes. Journal of Occupational and Environmental Medicine, 2011, 53, 981-991.	0.9	68
143	Drug Induced Non-Specific Interstitial Pneumonitis. , 2011, , .		0
144	Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival. Cancer, 2011, 117, 2186-2191.	2.0	67

#	Article	IF	Citations
145	Cytological, histological, and immunohistochemical findings of pulmonary carcinomas with basaloid features. Diagnostic Cytopathology, 2011, 39, 92-100.	0.5	24
146	Pleomorphic (Spindle and Squamous Cell) Carcinoma Arising in a Peripheral Mixed Squamous and Glandular Papilloma in a 70-Year-Old Man. Archives of Pathology and Laboratory Medicine, 2011, 135, 1353-1356.	1.2	21
147	Progression of Human Bronchioloalveolar Carcinoma to Invasive Adenocarcinoma Is Modeled in a Transgenic Mouse Model of K-rasâ€“Induced Lung Cancer by Loss of the TGF-Î² Type II Receptor. Cancer Research, 2011, 71, 6665-6675.	0.4	32
148	TGF-Â² Signaling Pathway in Lung Adenocarcinoma Invasion. Journal of Thoracic Oncology, 2010, 5, 153-157.	0.5	55
149	Computer-aided diagnosis of pulmonary nodules using a two-step approach for feature selection and classifier ensemble construction. Artificial Intelligence in Medicine, 2010, 50, 43-53.	3.8	104
150	Chronic Inflammation Promotes Tobacco Carcinogen Associated Tumors In Lung Cancer Susceptible (A/J) And Resistant (B6) Mice. , 2010, , .		0
151	Hypersensitivity Pneumonitis In A 20-month-old Child Due To Mycobacterium Avium Complex. , 2010, , .		0
152	CCR5 Small Molecule Inhibitors Reduce Invasion And Migration Of Lung Adenocarcinoma Cells. , 2010, , .		0
153	Stromal Cell Gene Signature Of Lung Adenocarcinoma Invasion. , 2010, , .		0
154	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis, 2010, 31, 577-586.	1.3	158
155	A Postinfluenza Model ofStaphylococcus aureusPneumonia. Journal of Infectious Diseases, 2010, 201, 508-515.	1.9	89
156	Sarcoidosis-Associated Fibrosing Mediastinitis with Resultant Pulmonary Hypertension: A Case Report and Review of the Literature. Respiration, 2010, 79, 341-345.	1.2	54
157	A Molecular Profile of Focal Segmental Glomerulosclerosis from Formalin-Fixed, Paraffin-Embedded Tissue. American Journal of Pathology, 2010, 177, 1674-1686.	1.9	104
158	Micropapillary Histology. American Journal of Clinical Pathology, 2009, 131, 615-617.	0.4	7
159	Genomics of Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 152-158.	3.5	36
160	Gene Expression Profiling of Pulmonary Fibrosis Identifies Twist1 as an Antiapoptotic Molecular â€œRectifierâ€•of Growth Factor Signaling. American Journal of Pathology, 2009, 175, 2351-2361.	1.9	55
161	Invasive Size is an Independent Predictor of Survival in Pulmonary Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 462-469.	2.1	178
162	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2009, 133, 1317-1331.	1.2	268

#	Article	IF	Citations
163	Impact of segmentation uncertainties on computer-aided diagnosis of pulmonary nodules. International Journal of Computer Assisted Radiology and Surgery, 2008, 3, 551-558.	1.7	3
164	A Two-Step Approach for Feature Selection and Classifier Ensemble Construction in Computer-Aided Diagnosis. , 2008, , .		15
165	Benign Tumors and Tumorlike Conditions of the Lung. Archives of Pathology and Laboratory Medicine, 2008, 132, 1133-1148.	1.2	22
166	Molecular Pathology of Large Cell Carcinoma and Its Precursors. Molecular Pathology Library, 2008, , 279-292.	0.1	0
167	Platelet-Derived Growth Factor Is Increased in Pulmonary Capillary Hemangiomatosis. Chest, 2007, 131, 850-855.	0.4	38
168	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest, 2007, 132, 998-1006.	0.4	223
169	Expression Profiling and Lung Cancer Development. Proceedings of the American Thoracic Society, 2007, 4, 127-132.	3.5	29
170	Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 193-201.	1.4	18
171	ENDOBRONCHIAL SCLEROSIS OF PULMONARY PARENCHYMA IN RATS. Chest, 2007, 132, 520A.	0.4	0
172	Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary MÃ¼llerian system origin?. Modern Pathology, 2007, 20, 856-863.	2.9	107
173	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	1.7	118
174	Fine needle aspiration biopsy of epithelioid hemangioendothelioma of the oral cavity: Report of one case and review of literature. Diagnostic Cytopathology, 2006, 34, 218-223.	0.5	30
175	Epigenetic Inactivation of Betaig-h3 Gene in Human Cancer Cells. Cancer Research, 2006, 66, 4566-4573.	0.4	46
176	A SECONDARY CARE PERSPECTIVE ON THE STEPPING-DOWN OF INHALED CORTICOSTEROID THERAPY IN PATIENTS WITH STABLE ASTHMA. Chest, 2005, 128, 242S.	0.4	4
177	Pulmonary Capillary Hemangiomatosis. Chest, 2005, 128, 575S-576S.	0.4	18
178	CDX2 Immunostaining as a Gastrointestinal Marker. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 55-60.	0.6	69
179	Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagnostic Cytopathology, 2005, 33, 65-70.	0.5	23
180	P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma. Clinical Cancer Research, 2005, 11, 3303-3308.	3.2	59

#	Article	IF	Citations
181	Lung Adenocarcinoma Global Profiling Identifies Type II Transforming Growth Factor-Î² Receptor as a Repressor of Invasiveness. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 729-737.	2.5	77
182	Molecular Signatures in Biopsy Specimens of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 167-174.	2.5	105
183	Unbalanced t(2;19) and t(2;16) in a neurofibroma. Cancer Genetics and Cytogenetics, 2004, 152, 169-171.	1.0	5
184	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer, 2004, 101, 1632-1638.	2.0	78
185	Silicosis in dental supply factory workers. Respiratory Medicine, 2004, 98, 791-794.	1.3	13
186	Non-small Cell Lung Cancer Molecular Profiles Are Associated With Lung Development. Chest, 2004, 125, 115S-116S.	0.4	0
187	Class Prediction of Lung Nodule Gene Expression Profiles. Chest, 2004, 125, 104S.	0.4	3
188	Histologic Assessment of Non-Small Cell Lung Carcinoma after Neoadjuvant Therapy. Modern Pathology, 2003, 16, 1102-1108.	2.9	46
189	Gene Expression in Lung Adenocarcinomas of Smokers and Nonsmokers. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 157-162.	1.4	112
190	Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways. American Journal of Pathology, 2003, 163, 1949-1960.	1.9	203
191	Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer, 2003, 39, 23-29.	0.9	30
192	The Heparan Sulfate ProteoglycanGPC3Is a Potential Lung Tumor Suppressor. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 694-701.	1.4	97
193	Sebaceous Carcinoma of the Lung: Histologic and Immunohistochemical Characterization of an Unusual Pulmonary Neoplasm. American Journal of Surgical Pathology, 2002, 26, 795-798.	2.1	38
194	Gene Expression in Wilmsâ€™ Tumor Mimics the Earliest Committed Stage in the Metanephric Mesenchymal-Epithelial Transition. American Journal of Pathology, 2002, 160, 2181-2190.	1.9	213